摘要
目的探讨帕立骨化醇和骨化三醇治疗尿毒症血透患者继发性甲状旁腺功能亢进症的治疗效果。方法随机选取2019年1月~2020年1月于我院就诊的尿毒症血透患者继发甲旁亢64例,其中将应用骨化三醇治疗的34例患者设为对照组,应用帕立骨化醇治疗的30例患者设为研究组,对比两组患者治疗后的效果及安全性。结果研究组患者用药后iPTH含量为(216.02±25.56)pmol/L、血清磷为(1.36±0.28)mmol/L、血清钙为(2.51±0.38)mmol/L和碱性磷酸酶含量为(72.39±3.61)mmol/L,结果均优于对照组,差异均有统计学意义(P<0.05);研究组患者用药后不良反应总发生率明显低于对照组,差异有统计学意义(P<0.05)。结论应用帕立骨化醇能够有效降低继发性甲旁亢患者iPTH的含量,且高钙血症和高磷血症的发生率较低,不良反应总发生率较低,相较于骨化三醇其效果更佳,安全性更好。
Objective To explore the therapeutic effects of paricalcitol and calcitriol in the treatment of uremic hemodialysis patients with secondary hyperparathyroidism.Methods A total of 64 uremic hemodialysis patients with secondary hyperparathyroidism who were treated in our hospital from January 2019 to January 2020 were randomly selected.Among them,34 patients treated with calcitriol were set as the control group.Thirty patients treated with paricalcitol were set as the study group.The effects and safety of the two groups after treatment were compared.Results The iPTH,serum phosphorus,serum calcium,and alkaline phosphatase content of patients with secondary hyperparathyroidism in the study group after the medication were(216.02±25.56)pmol/L,(1.36±0.28)mmol/L,(2.51±0.38)mmol/L,and(72.39±3.61)mmol/L,which were better than those of the control group,and the differences were significant(P<0.05).The total incidence of adverse reactions in the study group after the medication was lower than that in the control group,and the difference between the two groups was statistically significant(P<0.05).Conclusion The application of paricalcitol can effectively reduce the content of iPTH in patients with secondary hyperparathyroidism,which has a low incidence of hypercalcemia,hyperphosphatemia,and total adverse reactions.Compared with calcitriol,it has a better effect and better safety.
作者
陈燕
张英姿
姚霞娟
吴娱
胡宏
CHEN Yan;ZHANG Yingzi;YAO Xiajuan;WU Yu;HU Hong(Department of Nephrology,Jiangyin People's Hospital in Jiangsu Province,Jiangyin 214400,China)
出处
《中国现代医生》
2020年第34期52-54,59,共4页
China Modern Doctor
